ClinicalTrials.gg

Geographic Atrophy clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 188 studies for Geographic Atrophy across more than 10 countries. 52 are recruiting or about to start. 154 of them are mainly about Geographic Atrophy (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16.

Status

Completed
83
Recruiting
40
Terminated
24
Active, not recruiting
13
Withdrawn
8
Not yet recruiting
8

Phase

Phase 2
75
Phase 1
39
Phase 3
24
Phase 4
7
Early Phase 1
1

Where

United States
131
Australia
41
Germany
40
United Kingdom
38
Spain
32
France
30

Who develops what

Add Geographic Atrophy to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 22 programs from 17 companies, 21 with this as their studies’ main aim; 2 with a live phase 3 study; 6 primary completions in the next 12 months. Compare Hoffmann-La Roche, AbbVie and Boehringer Ingelheim here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
pegcetacoplanRecent, limited
Evidence
  • NCT06722157 · Boehringer Ingelheim · Phase 2 · comparator · “Pegcetacoplan” · registered Dec 2024
Biogen80% of its industry studiesUS: Biogen (FDA 2021)EU: Swedish Orphan Biovitrum (EMA 2021)11 study
PrednisoneRecent, limitedPhase 4 trial recorded
Evidence
  • NCT05811351 · Johnson & Johnson · Phase 2 · background · “Prednisone” · registered Mar 2023
Johnson & Johnson11% of its industry studies11 study
TriamcinoloneRecent, limitedPhase 4 trial recorded
Evidence
  • NCT05811351 · Johnson & Johnson · Phase 2 · background · “Triamcinolone” · registered Mar 2023
Research Insight LLC20% of its industry studies11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
vonaprument☆ Track2 live phase-3 studies: NCT06510816, NCT07807969Annexon, Inc.

The 1 in phase 3 with the nearest primary completion, of 22 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (6)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 22 Dec 2026 est.BI 1584862 · Boehringer Ingelheim · Phase 2 main aimNCT06769048 A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy — primary endpoint: Slope of change from baseline in square root transformed geographic atrophy (GA) area as measured by fundus autofluorescence (FAF) over a treatment period of up to 50 weeks (expressed in mm/year) in the study eye · 150 enrolled
  • 25 Jun 2027 est.pegcetacoplan · Biogen · Phase 2 main aimNCT07215390 A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio — primary endpoint: Change from baseline (CFB) in the area of artificial intelligence (AI)-based SD-OCT assessment of RPE lesion in the study eye · 240 enrolled
  • 30 Jun 2027 est.avacincaptad pegol · Astellas Pharma Inc · Phase 4 main aimNCT06970665 A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration — primary endpoint: Number of participants with Treatment Emergent Adverse Events (TEAEs) · 17 enrolled

3 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Geographic Atrophy studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Angiogenesis inhibitors 5

Coming up

17studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and 0 (0%) stop at 75 or younger. 2 (5%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 4 (10%) take healthy volunteers.

Recruiting studies that take each age, of 40
AgeWomenMen
102 (5%)2 (5%)
187 (18%)7 (18%)
307 (18%)7 (18%)
407 (18%)7 (18%)
5020 (50%)20 (50%)
6540 (100%)40 (100%)
7540 (100%)40 (100%)
8539 (98%)39 (98%)

Across all 188 studies, recruiting or not: 1% stop at 75 or younger and 1% at 65; 3% take children; 0% are for women only and 0% for men only; 9% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Geographic Atrophy studies take

Of 24 phase 2 interventional studies under Geographic Atrophy, half reached primary completion within 35 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 113 mo8–28 · 13 studies——
Phase 235 mo24–54 · 24 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 188. Browse all 188 → or search them.